| Pharmaceutical Information |
| Drug Name |
Muromonab-cd3 |
| Drug ID |
BADD_D01506 |
| Description |
Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a). |
| Indications and Usage |
For treatment of organ transplant recipients, prevention of organ rejection |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AA02 |
| DrugBank ID |
DB00075
|
| KEGG ID |
D05092
|
| MeSH ID |
D016853
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D05GVQ
|
| NDC Product Code |
Not Available |
| UNII |
JGA39ICE2V
|
| Synonyms |
Muromonab-CD3 | Muromonab CD3 | OKT3 | Monoclonal Antibody OKT3 | Orthoclone OKT3 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
140608-64-6 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
